462 results on '"Roobol M.J."'
Search Results
2. Differences in quality of curative treatment and outcome in men with localised prostate cancer in the screening and control arms of the ERSPC Rotterdam
3. Development of a predictive model for death amongst patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) treated with one of the approved treatment plans, on characteristics present at admission using Big data: Preliminary results from the European network of excellence for big data in prostate cancer (PIONEER)
4. The impact of prostate cancer ADT and EBRT follow-up treatment on patient-reported quality of life – results from the EUPROMS 2.0 follow-up study
5. Effect of age at first protocoled screening on long-term outcomes in prostate cancer screening: Results from a cross-sectional screening study
6. Why is there a need to re-think prostate cancer early detection?
7. Long-term sexual health of men on active surveillance for low-risk prostate cancer – results of the Movember GAP3 consortium
8. Treatment free survival and the pattern of follow-up treatments after curative prostate cancer treatment, a reflection of electronic health record data
9. Reasons for discontinuation of active surveillance and subsequent outcome on radical prostatectomy pathology
10. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium
11. Development of a prediction model in female pure or predominant urge urinary incontinence: a retrospective cohort study
12. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review
13. Clinical characterization and outcomes of prostate cancer patients undergoing immediate vs. conservative management: A PIONEER study
14. Shifting risk-stratified early detection of prostate cancer to primary health care
15. Identification of pathologic factors associated with intraoperative positive surgical margins at NeuroSAFE for clinical decision-making on nerve-sparing surgery
16. Quality of life for higher vs. lower educated men following active surveillance, radical prostatectomy or radiotherapy in the patient-initiated EUPROMS study
17. How long do men stay in intermediate stages between randomization and death: Results of ERSPC Rotterdam
18. Continence after introducing NeuroSAFE in radical prostatectomy
19. Mapping EAU guideline practice variations across Europe: An audit of ADT before surgery in locally advanced and high-risk prostate cancer in 6315 cases across 31 European countries
20. Active surveillance for prostate cancer: Uptake over time and the impact of an organized protocol
21. Twenty-year outcome of men participating in a screening trial with an initial negative prostate biopsy
22. Outcomes of importance to men with advanced prostate cancer: PIONEER interview study
23. Prostate cancer detection rate of transrectal versus transperineal MRI-TRUS fusion prostate biopsy: experience in 794 cases
24. External validation of a model predicting increase in Gleason grade for men on Active Surveillance in the GAP3 consortium database
25. Baseline PSA below 1.0 ng/ml, and then? Verification of the EAU 2021 Position and Recommendation on risk-adapted early detection using ERSPC Rotterdam data with more than 20 years of detailed follow-up
26. Complications after transrectal prostate biopsy with antibiotic prophylaxis versus transperineal without antibiotic prophylaxis: Comparison of two clinical practices
27. A comparison of the PLUM and RPCRC- MRI-based prostate cancer risk prediction models in two North American and European cohorts
28. Cribriform and intraductal carcinoma do not improve the nomogram-based selection of prostate cancer patients for pelvic lymph node dissection
29. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)
30. Nederlandse urologen geven hun visie op active surveillance
31. Risicostratificatie en vroege opsporing van prostaatkanker: Risicostratificatie en vroege opsporing van prostaatkanker
32. Secondary treatment for men with localized prostate cancer: A pooled analysis of PRIAS and ERSPC-Rotterdam datasets within the PIONEER data platform
33. A 2-arm pseudo-randomized multicenter (MR PROPER) trial: MRI-directed pathway outperforms TRUS-directed pathway in prostate cancer diagnosis following upfront risk stratification
34. Intraprostatic recurrences on PSMA PET/CT after prostate whole gland radiotherapy. Is histological confirmation necessary?
35. An MRI guided active surveillance strategy. Can the PRECISE score exclude reclassification?
36. The development of a dynamic prediction model using MRI predicting Gleason upgrading on prostate biopsy in patients on active surveillance
37. Prostate cancer specific mortality in the ERSPC trial: What is the role of screening result and adherence
38. Are reported sexual and urinary functioning in clinical studies an accurate representation of the burden after prostate cancer treatment: Results from the EUPROMS study
39. Diagnostic and prognostic factors in patients with prostate cancer
40. Reducing biopsies and mris in the diagnostic pathway of prostate cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION trial data
41. Outcomes after introducing intraoperative NeuroSAFE technique in robot-assisted radical prostatectomy
42. Sexual function of men undergoing invasive prostate cancer treatment versus active surveillance – Results of the EUPROMS study
43. Unchanged negative prostate mpMRI during active surveillance, is it still necessary to biopsy and follow-up?
44. Upfront MRI is the new standard, have confirmatory biopsies become obsolete?
45. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
46. IMAGINE-IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines
47. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission
48. Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy
49. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.
50. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.